Prior studies have illuminated the regulatory pathways of IRF4 in diverse disease contexts and its intimate association with tumor progression—notably, the work by Lopez-Girona A et al. revealed that immunomodulatory drugs (IMiDs) exert their tumor-suppressive effects by reducing IRF4 activity or expression levels, and this effect is modulated by the expression level of cereblon (CRBN) [29]. Here, CRBN is linked to neoplasm.